FDA approves Ipsen's Dysport for adult lower limb spasticity

FDA approved an sBLA to expand the label for Dysport abobotulinumtoxinA (Azzalure - EU) from Ipsen Group (Euronext:IPN; Pink:IPSEY) to treat lower limb spasticity in adults. The product is approved in the U.S. to treat lower limb spasticity in children, cervical dystonia, upper limb spasticity and for the temporary improvement of glabellar lines...